BioSpace8h
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
BioSpace9h
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies
The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...
BioSpace9h
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...
BioSpace9h
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...
BioSpace16h
FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...
BioSpace16h
Biopharma Takes on Deadly Brain Cancer After Decades of Failure
Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...
BioSpace16h
Digital Twins Could Augment Clinical Research, Help Ease Data Disparities
Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to ...